Mantle-Cell Lymphoma Accounting for 5 to 7% of all lymphomas, mantle-cell lymphoma has
historically been associated with a poor outcome, but survival is improving. The …

Unprecedented advances in our understanding of the pathobiology, prognostication, and
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …

Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma that is most
commonly treated with combination chemo-immunotherapy at diagnosis because of the …

PURPOSE The need for an individualized management of indolent clinical forms in mantle
cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment …

Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy, but some patients have a
very indolent evolution. This heterogeneous course is related, in part, to the different …

Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma (NHL) that is
incurable with standard therapies. The genetic drivers of this cancer have not been firmly …

This Guideline was compiled according to the BSH process at https://bs-41 h. org.
uk/media/16732/bsh-guidance-development-process-dec-5-18. pdf and 42 represents best …

Simple Summary Mantle cell lymphoma (MCL) is an aggressive lymphoid tumour with a
poor prognosis. There exist no routine biomarkers for the early prediction of relapse. Our …

Although an expanding array of effective treatments has resulted in recent improvement in
survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and …